These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37831445)

  • 1. Association of Subretinal Fluid Duration and Baseline Chorioretinal Structure With Optical Coherence Tomography in Central Serous Chorioretinopathy.
    Suzuki T; Sasajima H; Otaki C; Ueta Y; Tate H
    Transl Vis Sci Technol; 2023 Oct; 12(10):12. PubMed ID: 37831445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy.
    Li M; Qu J; Liang Z; Tang J; Hu J; Yao Y; Jin E; Li X; Zhao M
    Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2175-2182. PubMed ID: 35024912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between morphological characteristics in spectral-domain-optical coherence tomography, different functional tests and a patient's subjective handicap in acute central serous chorioretinopathy.
    Gerendas BS; Kroisamer JS; Buehl W; Rezar-Dreindl SM; Eibenberger KM; Pablik E; Schmidt-Erfurth U; Sacu S
    Acta Ophthalmol; 2018 Nov; 96(7):e776-e782. PubMed ID: 29338130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.
    Ohkuma Y; Hayashi T; Sakai T; Watanabe A; Tsuneoka H
    Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):1909-17. PubMed ID: 23456099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Subretinal Fluid Optical Density Ratio Differ Among the Eyes with Acute Central Serous Chorioretinopathy,Vogt Koyanagi Harada Disease and Choroidal Hemangioma: A Cross-sectional Study.
    Durmaz Engin C; Kayabasi M; Koksaldi S; Ipek SC; Saatci AO
    Photodiagnosis Photodyn Ther; 2023 Jun; 42():103634. PubMed ID: 37244453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term outer retinal changes in central serous chorioretinopathy submitted to half-dose photodynamic therapy.
    Torres-Costa S; Penas S; Cerqueira AR; Brandão E; Carneiro Â; Rocha-Sousa A; Falcão-Reis F
    Photodiagnosis Photodyn Ther; 2021 Jun; 34():102235. PubMed ID: 33631379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal choroidal flow on optical coherence tomography angiography in central serous chorioretinopathy.
    Seo EJ; Um T; Yoon YH
    Clin Exp Ophthalmol; 2019 May; 47(4):505-512. PubMed ID: 30515936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional configuration of subretinal fluid in central serous chorioretinopathy.
    Ahn SE; Oh J; Oh JH; Oh IK; Kim SW; Huh K
    Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):5944-52. PubMed ID: 23920371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHANGE OF CHOROIDAL VOLUME IN UNTREATED CENTRAL SEROUS CHORIORETINOPATHY.
    Pertl L; Haas A; Hausberger S; Pichler T; Rabensteiner DF; Seidel G; Malle EM; Weger M
    Retina; 2017 Sep; 37(9):1792-1796. PubMed ID: 27941529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The quantitative evaluation of retinal layers after resolution of subretinal fluid in acute central serous chorioretinopathy.
    Dursun E; Dursun GA
    Eur J Ophthalmol; 2022 Nov; ():11206721221136989. PubMed ID: 36325684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.
    Subhi Y; Bjerager J; Boon CJF; van Dijk EHC
    Acta Ophthalmol; 2022 Feb; 100(1):89-95. PubMed ID: 33998168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.
    Weber ML; Liang MC; Flaherty KT; Heier JS
    JAMA Ophthalmol; 2016 Aug; 134(8):855-62. PubMed ID: 27309887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.
    van Rijssen TJ; Mohabati D; Dijkman G; Theelen T; de Jong EK; van Dijk EHC; Boon CJF
    PLoS One; 2018; 13(8):e0202549. PubMed ID: 30142176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression patterns of central serous chorioretinopathy using en face optical coherence tomography.
    Arora S; Rosario B; Mohammed AR; Beale O; Selvam A; Venkatesh R; Maltsev DS; Chhablani J;
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2475-2481. PubMed ID: 35357548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy.
    Chen YC; Chen SN
    Br J Ophthalmol; 2020 Nov; 104(11):1561-1566. PubMed ID: 32051140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.
    Kim YK; Ryoo NK; Woo SJ; Park KH
    Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BASELINE SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AS A PREDICTOR OF VISUAL OUTCOME AND RECURRENCE FOR CENTRAL SEROUS CHORIORETINOPATHY.
    Lee H; Lee J; Chung H; Kim HC
    Retina; 2016 Jul; 36(7):1372-80. PubMed ID: 26702841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.